PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...
NORTHAMPTON, MA / ACCESS Newswire / April 1, 2025 / In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe ...
Vaccine makers were hit particularly hard yesterday, as Marks’ resignation letter alluded to disagreements with HHS Secretary ...
Barchart on MSN20h
These 2 Buy-Rated Dividend Stocks Could Be Next in Line for a Trump Tariff Selloff. Should You Jump Ship Now?President Donald Trump recently proposed tariffs on pharmaceutical imports from countries like Ireland and India, both key ...
News Medical on MSN4h
NIH funds research to develop a game-changing HIV diagnostic toolAs of the end of 2023, nearly 40 million people worldwide were living with HIV, including approximately 1.2 million in the ...
Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback